Skip to main content

NIH Seeking Assays for High-Throughput Screening of Chemical Probes

NEW YORK (GenomeWeb News) – The National Institutes of Health wants scientists to leverage new high-throughput screening-based technologies for discovering small molecule probes, and it will fund two new grant programs to fund collaborative research with HTS facilities aimed at translating these advances into assays for disease studies.

Several NIH institutes will support new projects to discover and develop small molecules for studies of diseases relevant to the institutes' missions and for discovery or validation of biological targets that will inform studies of disease mechanisms.

The funding level for the three-year R01 grants is not specifically limited and the R21 program will provide up to $275,000 over two years.

The awards are aimed at providing funding for investigators who will form a collaboration with an academic, nonprofit, or commercial high-throughput screening facility that has the expertise to implement an HTS-ready assay for the discovery and development of small molecule chemical probes. The facility should have the capability to optimize and automate biochemical, cellular, or whole-organism-based assays for screening a large library of compounds.

When the screening projects are completed, samples of initial hits will be picked for further confirmation by investigators who will implement secondary assays to remove false positive results. Additional follow-up assays also may be conducted to characterize the mode and mechanism of action of the validated hits.

Several NIH institutes will participate in the HTS program, including the National Institute of General Medical Sciences and the National Cancer Institute.

NIGMS is seeking assays that are relevant to basic research in genetics, cell biology, pharmacology, developmental biology, and other broad areas.

NCI will welcome high-throughput screens that are relevant to cancer including biochemical, cellular, or model-organism-based screens, and which may be used to develop strategies for cancer prevention or treatment or for clinical monitoring.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.